Targets for botulinum toxin in the lower urinary tract

Neurourology and Urodynamics

Volumn 33, Issue 1, 2014, Pages 31-38

  Cruz, Francisco ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

botulinum toxin type A; overactive bladder; SNAP 25

Indexed keywords

ADENOSINE TRIPHOSPHATE; BOTULINUM TOXIN A; GLUTAMIC ACID; NEUROPEPTIDE; NEUROTROPHIN; NORADRENALIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ACINAR CELL; APOPTOSIS; ARTICLE; BLADDER; BLADDER OBSTRUCTION; BLADDER WALL; CYSTITIS; EFFERENT NERVE; HUMAN; IMMUNOREACTIVITY; MYOFIBROBLAST; NONHUMAN; PARASYMPATHETIC NERVE CELL; PREGANGLIONIC NERVE CELL; PROSTATE; PROTEIN CLEAVAGE; PROTEIN TARGETING; SENSORY NERVE; SENSORY NERVE CELL; SPINAL CORD INJURY; STROMA CELL; SYMPATHETIC NERVE; URETHRA; UROTHELIUM;

BOTULINUM TOXIN TYPE A; OVERACTIVE BLADDER; SNAP-25;

ANIMALS; BOTULINUM TOXINS, TYPE A; HUMANS; NERVE FIBERS; NEUROMUSCULAR AGENTS; PRESYNAPTIC TERMINALS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; UROLOGICAL AGENTS; UROTHELIUM;

EID: 84890312596     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22445     Document Type: Article

References (74)

1. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 742-50.
2. Nitti VW, Dmochowski R, Herschorn S, et al. EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J Urol 2012; 189: 2186-93.
3. Dykstra DD, Sidi AA,. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch Phys Med Rehabil 1990; 71: 24-6.
4. Schurch B, Schmid DM, Stöhrer M,. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.
5. Chancellor MB, Fowler CJ, Apostolidis A, et al. Drug Insight: Biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008; 5: 319-28.
6. Apostolidis A, Dasgupta P, Denys P, et al. European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report. Eur Urol 2009; 55: 100-19.
7. Charrua A, Avelino A, Cruz F,. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. Handb Exp Pharmacol 2011; 202: 345-74.
8. Fernandez-Salas E, Wang J, Molina Y, et al. Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS ONE 2012; 7: e49516. doi: 10.1371/journal.pone.0049516
9. Smith TJ, Lou J, Geren IN, et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 2005; 73: 5450-7.
10. Arndt JW, Jacobson MJ, Abola EE, et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 2006; 362: 733-42.
11. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-6.
12. Humeau Y, Doussau F, Grant NJ, et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000; 82: 427-46.
13. Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010; 57: 884-90.
14. Coelho A, Cruz F, Cruz CD, et al. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol 2012; 61: 1178-84.
15. Coelho A, Cruz F, Cruz CD, et al. Effect of onabotulinumtoxinA on intramural parasympathetic ganglia: An experimental study in the guinea pig bladder. J Urol 2012; 187: 1121-6.
16. Schulte-Baukloh H, Zurawski TH, Knispel HH, et al. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 2007; 100: 1075-80.
17. Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009; 182: 786-92.
18. Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, et al. Intravesical electromotive botulinum toxin type A administration-Part II: Clinical application. Urology 2011; 77: 439-45.
19. Mehnert U, Boy S, Schmid M, et al. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 2009; 27: 397-403.
20. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169: 1896-900.
21. Burnstock G,. The changing face of autonomic neurotransmission. Acta Physiol Scand 1986; 126: 67-91.
22. Andersson PO, Bloom SR, Mattiasson A, et al. Bladder vasodilatation and release of vasoactive intestinal polypeptide from the urinary bladder of the cat in response to pelvic nerve stimulation. J Urol 1987; 138: 671-3.
23. Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol 2010; 184: 2578-85.
24. Iijima K, De Wachter S, Wyndaele JJ,. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007; 52: 842-7.
25. O'Reilly BA, Kosaka AH, Knight GF, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002; 167: 157-64.
26. Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol 2004; 46: 247-53.
27. Schulte-Baukloh H, Priefert J, Knispel HH, et al. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X 2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: A single-blind study. Urology 2013; 81: 1052-57.
28. Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol 2012; 62: 1157-64.
29. Speakman MJ, Brading AF, Gilpin CJ, et al. Bladder outflow obstruction-A cause of denervation supersensitivity. J Urol 1987; 138: 1461-6.
30. Howles S, Curry J, McKay I, et al. Lack of effectiveness of botulinum neurotoxin A on isolated detrusor strips and whole bladders from mice and guinea-pigs in vitro. BJU Int 2009; 104: 1524-9.
31. Rapp DE, Turk KW, Bales GT, et al. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006; 175: 1138-42.
32. Duggan MJ, Quinn CP, Chaddock JA, et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 2002; 277: 34846-52.
33. Kawatani M, Nagel J, de Groat WC,. Identification of neuropeptides in pelvic and pudendal nerve afferent pathways to the sacral spinal cord of the cat. J Comp Neurol 1986; 249: 117-32.
34. Keast JR, de Groat WC,. Immunohistochemical characterization of pelvic neurons which project to the bladder, colon, or penis in rats. J Comp Neurol 1989; 288: 387-400.
35. Morenilla-Palao C, Planells-Cases R, García-Sanz N, et al. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004; 279: 25665-72.
36. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-82.
37. Giannantoni A, Costantini E, Di Stasi SM, et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study. Eur Urol 2006; 49: 704-9.
38. Liu H-t, Chancellor MB,., Kuo H-C,. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009; 56: 700-6.
39. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-5.
40. Vemulakonda VM, Somogyi GT, Kiss S, et al. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005; 173: 621-4.
41. Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: A systematic review. Eur Urol 2012; 61: 29-53.
42. Kuo HC, Chancellor MB,. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009; 104: 657-61.
43. Pinto R, Lopes T, Silva J, et al. Persistent therapeutic effect of Onabotulinum Toxin A in refractory bladder pain syndrome/interstitial cystitis. J Urol 2013; 189: 548-53.
44. Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med 2010; 11: 1827-33.
45. Drake MJ, Harvey IJ, Gillespie JI, et al. Localized contractions in the normal human bladder and in urinary urgency. BJU Int 2005; 95: 1002-5.
46. Andersson KE, Arner A,. Urinary bladder contraction and relaxation: Physiology and pathophysiology. Physiol Rev 2004; 84: 935-86.
47. Lundberg JM, Hökfelt T,. Multiple co-existence of peptides and classical transmitters in peripheral autonomic and sensory neurons-Functional and pharmacological implications. Prog Brain Res 1986; 68: 241-62.
48. Pinto R, Lopes T, Silva J, et al. Urinary levels of noradrenaline are increased in patients with bladder pain syndrome/interstitial cystitis and are decreased by intratrigonal onabotulinum toxin type A injection. Eur Urol Suppl 2012; 11: e997a.
49. Birder LA, de Groat WC,. Mechanisms of disease: Involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007; 4: 46-54.
50. Birder LA, Kanai AJ, de Groat WC, et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 2001; 98: 13396-401.
51. Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2×3-deficient mice. Nature 2000; 407: 1011-5.
52. Ozawa H, Chancellor MB, Jung SY, et al. Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol 1999; 162: 2211-6.
53. Pandita RK, Mizusawa H, Andersson KE,. Intravesical oxyhemoglobin initiates bladder overactivity in conscious, normal rats. J Urol 2000; 164: 545-50.
54. Khera M, Somogyi GT, Kiss S, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45: 987-93.
55. Smith CP, Vemulakonda VM, Kiss S, et al. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: Effect of botulinum toxin A. Neurochem Int 2005; 47: 291-7.
56. Smith CP, Gangitano DA, Munoz A, et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 2008; 52: 1068-75.
57. Barrick SR, de Groat WC, Birder LA, et al. Regulation of chemical and mechanical-evoked ATP release from urinary bladder urothelium by botulinum toxin type A. Soc Neurosci Abstr View 2004; 541: 5.
58. Banerjee A, Li G, Alexander EA, et al. Role of SNAP-23 in trafficking of H+-ATPase in cultured inner medullary collecting duct cells. Am J Physiol Cell Physiol 2001; 280: C775- C781.
59. McCloskey KD,. Interstitial cells in the urinary bladder-Localization and function. Neurourol Urodyn 2010; 29: 82-7.
60. Wiseman OJ, Fowler CJ, Landon DN,. The role of the human bladder lamina propria myofibroblast. BJU Int 2003; 91: 89-93.
61. Apostolidis A, Dasgupta P, Fowler CJ,. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50.
62. Roosen A, Datta SN, Chowdhury RA, et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 2009; 55: 1440-8.
63. Compérat E, Reitz A, Delcourt A, et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity-A comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006; 50: 1058-64.
64. Kessler TM, Khan S, Panicker JN, et al. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: Preliminary results. Eur Urol 2010; 57: 879-83.
65. Chuang YC, Chiang PH, Huang CC, et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66: 775-9.
66. Silva A, Cruz CD, Charrua A, et al. GRC 6211 a new oral TRPV1 antagonist, decreases neurogenic detrusor overactivity in a rat model of spinal cord transection. Neurourol Urodyn 2008; 27: 597-8.
67. Silva J, Pinto R, Carvallho T, et al. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: An experimental study in the rat. Eur Urol 2009; 56: 134-40.
68. Doggweiler R, Zermann DH, Ishigooka M, et al. Botox-induced prostatic involution. Prostate 1998; 37: 44-50.
69. Chuang YC, Tu CH, Huang CC, et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006; 6: 12. doi: 10.1186/1471-2490-6-12
70. Gorgal T, Charrua A, Silva JF, et al. Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection. BMC Urol 2012; 12: 1. doi: 10.1186/1471-2490-12.1
71. Lin AT, Yang AH, Chen KK,. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52: 582-9.
72. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003; 62: 259-64.
73. Silva J, Pinto R, Carvalho T, et al. Intraprostatic botulinum toxin type A administration: Evaluation of the effects on sexual function. BJU Int 2011; 107: 1950-4.
74. Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial. J Urol 2011; 186: 965-70.